Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies

The recent success of checkpoint blockers to treat cancer has demonstrated that the immune system is a critical player in the war against cancer. Historically, anticancer therapeutics have been tested in syngeneic mouse models (with a fully murine immune system) or in immunodeficient mice that allow...

Descripción completa

Detalles Bibliográficos
Autor: Fernández-de-Sanmamed-Gutiérrez, M. (Miguel)|||/items/35ac602c-f0ff-4664-bbd2-506afc96db09
Tipo de recurso: artículo
Fecha de publicación:2016
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/113620
Acceso en línea:https://hdl.handle.net/10171/113620
Access Level:acceso abierto
Palabra clave:Checkpoint blocker
Humanized mice
Immunotherapy
Murine model
Tumor microenvironment
id ES_a5c3a3e528fa3f5db18cf4e8c3cf09cf
oai_identifier_str oai:dadun.unav.edu:10171/113620
network_acronym_str ES
network_name_str España
repository_id_str
spelling Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapiesFernández-de-Sanmamed-Gutiérrez, M. (Miguel)|||/items/35ac602c-f0ff-4664-bbd2-506afc96db09Checkpoint blockerHumanized miceImmunotherapyMurine modelTumor microenvironmentThe recent success of checkpoint blockers to treat cancer has demonstrated that the immune system is a critical player in the war against cancer. Historically, anticancer therapeutics have been tested in syngeneic mouse models (with a fully murine immune system) or in immunodeficient mice that allow the engraftment of human xenografts. Animal models with functioning human immune systems are critically needed to more accurately recapitulate the complexity of the human tumor microenvironment. Such models are integral to better predict tumor responses to both immunomodulatory agents and directly antineoplastic therapies. In this regard, the development of humanized models is a promising, novel strategy that offers the possibility of testing checkpoint blockers' capacity and their combination with other antitumor drugs. In this review, we discuss the strengths and weaknesses of the available animal models regarding their capacity to evaluate checkpoint blockers and checkpoint blocker-based combination immunotherapy.Oxford University PressDadun. Depósito Académico Digital Universidad de Navarra20162016-01-0120162016-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/113620reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/1136202026-06-21T12:47:57Z
dc.title.none.fl_str_mv Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
title Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
spellingShingle Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
Fernández-de-Sanmamed-Gutiérrez, M. (Miguel)|||/items/35ac602c-f0ff-4664-bbd2-506afc96db09
Checkpoint blocker
Humanized mice
Immunotherapy
Murine model
Tumor microenvironment
title_short Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
title_full Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
title_fullStr Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
title_full_unstemmed Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
title_sort Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
dc.creator.none.fl_str_mv Fernández-de-Sanmamed-Gutiérrez, M. (Miguel)|||/items/35ac602c-f0ff-4664-bbd2-506afc96db09
author Fernández-de-Sanmamed-Gutiérrez, M. (Miguel)|||/items/35ac602c-f0ff-4664-bbd2-506afc96db09
author_facet Fernández-de-Sanmamed-Gutiérrez, M. (Miguel)|||/items/35ac602c-f0ff-4664-bbd2-506afc96db09
author_role author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv Checkpoint blocker
Humanized mice
Immunotherapy
Murine model
Tumor microenvironment
topic Checkpoint blocker
Humanized mice
Immunotherapy
Murine model
Tumor microenvironment
description The recent success of checkpoint blockers to treat cancer has demonstrated that the immune system is a critical player in the war against cancer. Historically, anticancer therapeutics have been tested in syngeneic mouse models (with a fully murine immune system) or in immunodeficient mice that allow the engraftment of human xenografts. Animal models with functioning human immune systems are critically needed to more accurately recapitulate the complexity of the human tumor microenvironment. Such models are integral to better predict tumor responses to both immunomodulatory agents and directly antineoplastic therapies. In this regard, the development of humanized models is a promising, novel strategy that offers the possibility of testing checkpoint blockers' capacity and their combination with other antitumor drugs. In this review, we discuss the strengths and weaknesses of the available animal models regarding their capacity to evaluate checkpoint blockers and checkpoint blocker-based combination immunotherapy.
publishDate 2016
dc.date.none.fl_str_mv 2016
2016-01-01
2016
2016-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/113620
url https://hdl.handle.net/10171/113620
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415642692583425
score 15.81155

Similares en LA Referencia